Aethlon Medical Cmn (AEMD) 6.28 $AEMD
Aethlon Medical Announces Fiscal 2017 First Quarter Results
PR Newswire - Thu Aug 11, 3:15PM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal first quarter year ended June 30, 2016.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Zika Virus Data
PR Newswire - Thu Aug 11, 8:12AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies. At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study. The Zika studies, which were conducted with small-scale versions of the Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours.
AEMD: 6.28 (-0.20)
Aethlon Medical To Host First Quarter Fiscal 2017 Investor Call On August 11, 2016
PR Newswire - Tue Aug 09, 11:07AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its First Quarter Fiscal 2017 investor conference call and webcast on Thursday, August 11, 2016 at 4:30 p.m. Eastern Time.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Issuance Of Exosome Capture Patent
PR Newswire - Tue Jun 14, 9:28AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that U.S. Patent Number 9,364,601 (the "601 Patent"
, related to methods for capturing an exosome from a patient, has been issued to the Company by the United States Patent and Trademark Office. The 601 Patent is an important addition to Aethlon's patent portfolio as it protects lectin-based exosome harvesting, diagnostics and therapeutic applications. In recent years, exosomes have emerged to become significant biomarker and therapeutic targets underlying a wide range of disease conditions, including cancer.
AEMD: 6.28 (-0.20)
Aethlon Medical To Present Cancer And Infectious Disease Initiatives, As Well As Chronic Traumatic Encephalopathy (CTE) Candidate Biomarker Discovery At Tomorrow's BIO International Convention
PR Newswire - Mon Jun 06, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting tomorrow (June 7th) at the BIO International Convention being held at Moscone Center in San Francisco, California. The presentation, which is scheduled to begin at 10:45AM (PT), will review Aethlon Medical's initiatives to combat cancer and infectious disease. Mr. Joyce will also present the discovery of a non-invasive candidate biomarker to diagnose CTE that was made in collaboration with Exosome Sciences, a majority-owned subsidiary of Aethlon Medical. CTE is a neurological disorder associated with exposure to repetitive head impacts, such as those experienced by American football players. At present, CTE can only be definitively diagnosed through post-mortem autopsy. The presentation can be accessed on-line through the following link: http://www.veracast.com/webcasts/bio/internat...220202.cfm
AEMD: 6.28 (-0.20)
Aethlon Medical To Present At 2nd Annual Sachs Associates Immuno-oncology: BD&L And Investment Forum On June 3, 2016
PR Newswire - Wed Jun 01, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum (http://www.sachsforum.com/2nd-immuno-oncology-bdl-and-investment-forum.html) at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL at 10:20 p.m. Central Time on Friday, June 3, 2016.
AEMD: 6.28 (-0.20)
Aethlon Medical's CEO and Executive Chairman James Joyce Interviewed by The Life Sciences Report
Marketwired - Thu May 05, 8:02AM CDT
SAN FRANCISCO, CA--(Marketwired - May 05, 2016) - Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (NASDAQ: AEMD), is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals.
AEMD: 6.28 (-0.20)
Aethlon Medical's Exosome Sciences Announces Production of ELLSA Exosome Isolation Platform
PR Newswire - Wed May 04, 8:30AM CDT
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc., (Nasdaq: AEMD) announced today that it will initiate production of its ELLSA(TM) (Enzyme Linked Lectin Specific Assay) diagnostic platform to isolate disease-specific exosomes from bodily fluids. Exosome Sciences, Inc. (ESI) will make the platform available to collaborative institutes that are conducting research on exosomal biomarkers with the eventual goal of supporting a new generation of diagnostic products.
AEMD: 6.28 (-0.20)
Aethlon Medical (AEMD) CEO Note: Hemopurifier Clinical Progression, USA Today on the Next Zika, Combating Bioterror & Pandemic Threats
PR Newswire - Mon May 02, 7:45AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
AEMD: 6.28 (-0.20)
FinancialBuzz.com Exclusive NASDAQ MarketSite Interview with Aethlon Medical, Inc. CEO James Joyce
PR Newswire - Tue Apr 05, 8:00AM CDT
www.FinancialBuzz.com, a leader in the financial media and news space, today announces an exclusive HD video interview with Aethlon Medical, Inc. (NASDAQ: AEMD) Chairman & CEO James Joyce from the floor of the NASDAQ MarketSite.
AEMD: 6.28 (-0.20)
Aethlon Medical Discloses Hemopurifier® Clinical Trial and Manufacturing Advancements
PR Newswire - Thu Mar 31, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), reported that the recently appointed principal investigator of its FDA approved clinical study in Houston, Texas, has completed a six-treatment protocol of Hemopurifier therapy in an enrolled patient and has consented the enrollment of the next patient. The information was disclosed during an Annual Meeting of Stockholders conducted on March 29, 2016 in San Diego, California. Aethlon had previously disclosed in February 2016, that it had completed the formal training of its new principal investigator, Dr. Ronald Ralph, and had additionally trained two sub-principal investigators to support the advancement of its clinical study.
AEMD: 6.28 (-0.20)
Aethlon Medical, Inc. Reports Annual Meeting Results
PR Newswire - Wed Mar 30, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of its Annual Meeting of Stockholders completed on March 29, 2016 in San Diego, California.
AEMD: 6.28 (-0.20)
Aethlon Medical To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 16, 2016
PR Newswire - Wed Mar 09, 5:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 28th Annual Growth Stock Conference in Laguna Niguel, CA at 10:30 a.m. PT (1:30 p.m. ET) on Wednesday, March 16, 2016.
AEMD: 6.28 (-0.20)
Aethlon Medical to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016
PR Newswire - Fri Feb 05, 8:32AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in New York, NY at 2:15 p.m. ET on Wednesday, February 10, 2016. Mr. Joyce will also participate in an Immunotherapy Panel discussion taking place at 3:15 p.m. ET.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Fiscal 2016 Third Quarter Results
PR Newswire - Thu Feb 04, 3:10PM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the third quarter of fiscal 2016 ended December 31, 2015.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Dengue Virus Study Approval, Chikungunya Virus Capture Data and Completion of U.S. Principal Investigator Training
PR Newswire - Wed Feb 03, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that a human treatment study entitled: "A Clinical Safety Study of the Aethlon Hemopurifier® in Patients with Dengue Virus Infection," has been approved by the Institutional Ethics Committee (IEC) at the MAX Super Specialty Hospital in Delhi, India. The Aethlon Hemopurifier is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.
AEMD: 6.28 (-0.20)
Aethlon Medical to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the BIO CEO & Investor Conference in New York, NY at 3:30 p.m. ET on Tuesday, February 9, 2016.
AEMD: 6.28 (-0.20)
Aethlon Medical To Host Third Quarter Fiscal 2016 Investor Call on February 4, 2016
PR Newswire - Fri Jan 29, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Third Quarter Fiscal 2016 investor conference call and webcast on Thursday, February 4, 2016 at 4:30 p.m. Eastern Time.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Fiscal 2017 First Quarter Results
PR Newswire - Thu Aug 11, 3:15PM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal first quarter year ended June 30, 2016.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Zika Virus Data
PR Newswire - Thu Aug 11, 8:12AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, announced today that its researchers have completed in vitro studies that demonstrate the rapid capture of Zika virus by the Aethlon Hemopurifier®. The Hemopurifier® is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies. At present, the immunotherapeutic technology is being advanced through an FDA approved human feasibility study. The Zika studies, which were conducted with small-scale versions of the Hemopurifier®, demonstrated a 95% clearance of Zika virus from cell culture fluid in 5.5 hours and an approximate 50% clearance of Zika from human blood serum in 5 hours.
AEMD: 6.28 (-0.20)
Aethlon Medical To Host First Quarter Fiscal 2017 Investor Call On August 11, 2016
PR Newswire - Tue Aug 09, 11:07AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that it will host its First Quarter Fiscal 2017 investor conference call and webcast on Thursday, August 11, 2016 at 4:30 p.m. Eastern Time.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Issuance Of Exosome Capture Patent
PR Newswire - Tue Jun 14, 9:28AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that U.S. Patent Number 9,364,601 (the "601 Patent"
, related to methods for capturing an exosome from a patient, has been issued to the Company by the United States Patent and Trademark Office. The 601 Patent is an important addition to Aethlon's patent portfolio as it protects lectin-based exosome harvesting, diagnostics and therapeutic applications. In recent years, exosomes have emerged to become significant biomarker and therapeutic targets underlying a wide range of disease conditions, including cancer. AEMD: 6.28 (-0.20)
Aethlon Medical To Present Cancer And Infectious Disease Initiatives, As Well As Chronic Traumatic Encephalopathy (CTE) Candidate Biomarker Discovery At Tomorrow's BIO International Convention
PR Newswire - Mon Jun 06, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, will be presenting tomorrow (June 7th) at the BIO International Convention being held at Moscone Center in San Francisco, California. The presentation, which is scheduled to begin at 10:45AM (PT), will review Aethlon Medical's initiatives to combat cancer and infectious disease. Mr. Joyce will also present the discovery of a non-invasive candidate biomarker to diagnose CTE that was made in collaboration with Exosome Sciences, a majority-owned subsidiary of Aethlon Medical. CTE is a neurological disorder associated with exposure to repetitive head impacts, such as those experienced by American football players. At present, CTE can only be definitively diagnosed through post-mortem autopsy. The presentation can be accessed on-line through the following link: http://www.veracast.com/webcasts/bio/internat...220202.cfm
AEMD: 6.28 (-0.20)
Aethlon Medical To Present At 2nd Annual Sachs Associates Immuno-oncology: BD&L And Investment Forum On June 3, 2016
PR Newswire - Wed Jun 01, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum (http://www.sachsforum.com/2nd-immuno-oncology-bdl-and-investment-forum.html) at the Hyatt Chicago Magnificent Mile Hotel in Chicago, IL at 10:20 p.m. Central Time on Friday, June 3, 2016.
AEMD: 6.28 (-0.20)
Aethlon Medical's CEO and Executive Chairman James Joyce Interviewed by The Life Sciences Report
Marketwired - Thu May 05, 8:02AM CDT
SAN FRANCISCO, CA--(Marketwired - May 05, 2016) - Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (NASDAQ: AEMD), is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals.
AEMD: 6.28 (-0.20)
Aethlon Medical's Exosome Sciences Announces Production of ELLSA Exosome Isolation Platform
PR Newswire - Wed May 04, 8:30AM CDT
Exosome Sciences, Inc., in collaboration with majority shareholder Aethlon Medical, Inc., (Nasdaq: AEMD) announced today that it will initiate production of its ELLSA(TM) (Enzyme Linked Lectin Specific Assay) diagnostic platform to isolate disease-specific exosomes from bodily fluids. Exosome Sciences, Inc. (ESI) will make the platform available to collaborative institutes that are conducting research on exosomal biomarkers with the eventual goal of supporting a new generation of diagnostic products.
AEMD: 6.28 (-0.20)
Aethlon Medical (AEMD) CEO Note: Hemopurifier Clinical Progression, USA Today on the Next Zika, Combating Bioterror & Pandemic Threats
PR Newswire - Mon May 02, 7:45AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
AEMD: 6.28 (-0.20)
FinancialBuzz.com Exclusive NASDAQ MarketSite Interview with Aethlon Medical, Inc. CEO James Joyce
PR Newswire - Tue Apr 05, 8:00AM CDT
www.FinancialBuzz.com, a leader in the financial media and news space, today announces an exclusive HD video interview with Aethlon Medical, Inc. (NASDAQ: AEMD) Chairman & CEO James Joyce from the floor of the NASDAQ MarketSite.
AEMD: 6.28 (-0.20)
Aethlon Medical Discloses Hemopurifier® Clinical Trial and Manufacturing Advancements
PR Newswire - Thu Mar 31, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), reported that the recently appointed principal investigator of its FDA approved clinical study in Houston, Texas, has completed a six-treatment protocol of Hemopurifier therapy in an enrolled patient and has consented the enrollment of the next patient. The information was disclosed during an Annual Meeting of Stockholders conducted on March 29, 2016 in San Diego, California. Aethlon had previously disclosed in February 2016, that it had completed the formal training of its new principal investigator, Dr. Ronald Ralph, and had additionally trained two sub-principal investigators to support the advancement of its clinical study.
AEMD: 6.28 (-0.20)
Aethlon Medical, Inc. Reports Annual Meeting Results
PR Newswire - Wed Mar 30, 8:30AM CDT
Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of its Annual Meeting of Stockholders completed on March 29, 2016 in San Diego, California.
AEMD: 6.28 (-0.20)
Aethlon Medical To Present At Roth Capital Partners 28th Annual Growth Stock Conference On March 16, 2016
PR Newswire - Wed Mar 09, 5:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the ROTH Capital Partners 28th Annual Growth Stock Conference in Laguna Niguel, CA at 10:30 a.m. PT (1:30 p.m. ET) on Wednesday, March 16, 2016.
AEMD: 6.28 (-0.20)
Aethlon Medical to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 10, 2016
PR Newswire - Fri Feb 05, 8:32AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in New York, NY at 2:15 p.m. ET on Wednesday, February 10, 2016. Mr. Joyce will also participate in an Immunotherapy Panel discussion taking place at 3:15 p.m. ET.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Fiscal 2016 Third Quarter Results
PR Newswire - Thu Feb 04, 3:10PM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the third quarter of fiscal 2016 ended December 31, 2015.
AEMD: 6.28 (-0.20)
Aethlon Medical Announces Dengue Virus Study Approval, Chikungunya Virus Capture Data and Completion of U.S. Principal Investigator Training
PR Newswire - Wed Feb 03, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that a human treatment study entitled: "A Clinical Safety Study of the Aethlon Hemopurifier® in Patients with Dengue Virus Infection," has been approved by the Institutional Ethics Committee (IEC) at the MAX Super Specialty Hospital in Delhi, India. The Aethlon Hemopurifier is a leading broad-spectrum treatment countermeasure against viral pathogens that are untreatable with or resistant to antiviral drug therapies.
AEMD: 6.28 (-0.20)
Aethlon Medical to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Mon Feb 01, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the BIO CEO & Investor Conference in New York, NY at 3:30 p.m. ET on Tuesday, February 9, 2016.
AEMD: 6.28 (-0.20)
Aethlon Medical To Host Third Quarter Fiscal 2016 Investor Call on February 4, 2016
PR Newswire - Fri Jan 29, 8:30AM CST
Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced that it will host its Third Quarter Fiscal 2016 investor conference call and webcast on Thursday, February 4, 2016 at 4:30 p.m. Eastern Time.
AEMD: 6.28 (-0.20)
